The endocrine therapy drugs (ETDs) market involves drugs that treat hormone-receptor-positive breast cancers. These drugs work by blocking the effects of estrogen and other hormones on cancer cell growth. Some common ETDs include selective estrogen receptor modulators (SERMs), aromatase inhibitors, and other agents. The use of ETDs has significantly improved outcomes for the majority of patients with hormone receptor-positive breast cancers. They are usually prescribed after surgery to reduce the risk of recurrence and improve survival rates. The global population's increasing longevity as well as rising incidence of breast cancer has fueled demand for ETDs.
The Global Endocrine Therapy Drugs (ETDs) Market is estimated to be valued at US$ 35060.96 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period from 2024 to 2031. The growth can be attributed to growing awareness about breast cancer targeted therapies and the expanding therapeutic applications of ETDs.
Key Takeaways
Key players operating in the Endocrine Therapy Drugs (ETDs) are Johnson & Johnson (US), Procter & Gamble (US), Kimberly-Clark (US), Essity Aktiebolag (publ) (Sweden), Kao Corporation (Japan), Daio Paper Corporation (Japan), Unicharm Corporation (Japan), Premier FMCG (South Africa), Ontex (Belgium), Hengan International Group Company Ltd. (China), Drylock Technologies (Belgium), Natracare LLC (US), First Quality Enterprises, Inc. (US), Bingbing Paper Co., Ltd. (China). Increasing demand for hormonal breast cancer therapies is prompting leading pharmaceutical companies to invest more in R&D for novel and improved ETD formulations.
Significant opportunities lie in expanding the scope of Endocrine Therapy Drugs Market Demand to complementary indications such as DCIS and metastatic breast cancers. ETDs with reduced side effects also represent an avenues for market growth. Geographically, Asia Pacific is witnessing rising sales of ETDs owing to improving awareness, screening rates and healthcare infrastructure in developing nations. Global expansion strategies by major players also drive the regional markets.
Market Drivers:
Increased Awareness of Cancer Targeted Therapies: Growing cancer awareness activities by private organizations as well as governments have highlighted the importance of targeted therapies like ETDs. This is a major factor propelling the ETDs market.
Market Restrains:
Side Effects of ETDs: Though ETDs significantly improve outcomes, they can cause several side effects like hot flashes, vaginal dryness, bone loss, and joint pain. Managing side effects poses challenges to wider acceptance and adherence.
Segment Analysis
The endocrine therapy drugs market is segmented into selective estrogen receptor modulators (SERMs), aromatase inhibitors, and gonadotropin-releasing hormone (GnRH) agonists. The aromatase inhibitors segment held a dominating share of the market in 2024 owing to high efficacy and minimal side effects associated with the drugs in this category. Aromatase inhibitors help lower estrogen levels in postmenopausal women by blocking the enzyme aromatase, which is responsible for the conversion of androgens into estrogens. They are commonly used in the treatment of hormone receptor-positive breast cancer.
Global Analysis
The North America region held the largest share of the endocrine therapy drugs market in 2024 due to strong presence of key industry players and increasing incidence of breast cancer in the region. According to the American Cancer Society, breast cancer is the most common cancer in American women, except for skin cancers. Favorable reimbursement policies and high awareness regarding cancer treatment are other factors expected to drive market growth. The Asia Pacific region is anticipated to grow at the fastest CAGR over the forecast period owing to rising healthcare spending, large patient pool, and improving accessibility to cancer treatment. Furthermore, rapid urbanization and growing geriatric population in countries such as China and India are aiding the market expansion in the region. An emerging middle class demographic and potential for generic drug industry growth also supports the projected growth rate.
Get more insights on Endocrine Therapy Drugs Market
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
